8,111 Results

Celgene acquires Juno Therapeutics and with JCAR 017

 Added 16 hours ago

Celgene Corporation and Juno Therapeutics, Inc. have announced the signing of a definitive merger agreement.

Chronic lymphocytic leukaemia treatment to be removed

 Added 16 hours ago

Genmab announces it is removing Arzerra from the chronic lymphocytic leukaemia market outside the US.

Five-year study of NX 1207 shows cut in surgery or radiotherapy for prostate cancer patients.

 Added 16 hours ago

Nymox Pharmaceutical reported top-line 5-year results from Nymox's U.S. Study NX03-0040 of NX 1207 (fexapotide triflutate) in prostate cancer. 

EC approves Adcetris for CD30-positive cutaneous T-cell lymphoma.

 Added 16 hours ago

The European Commission (EC) extended the current conditional marketing authorization of Adcetris (brentuximab vedotin).

Phase III study of Cinqair did not meet endpoint in Severe Eosinophilic Asthma.

 Added 16 hours ago

No reduction in the frequency of clinical asthma exacerbations (CAEs).

Investigational DNA vaccine in unsuccessful trial

 Added 16 hours ago

Phase III HELIOS trial of ASP 0113 fails to meet endpoints in cytomegalovirus.

FDA grants extended approval for Trisenox to treat acute promyelocytic leukemia

 Added 16 hours ago

The approval was based on a Priority Review by the FDA on data from published scientific literature and a review of Teva’s global safety database for arsenic trioxide.

Load more